Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
4
80%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Not yet recruiting5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 34 (80.0%)

Trials by Status

not_yet_recruiting5100%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingphase_3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years

NCT07505888
not_yet_recruitingphase_3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months

NCT07505836
not_yet_recruitingphase_3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months

NCT07505823
not_yet_recruitingphase_3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months

NCT07505810
not_yet_recruitingphase_2

Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above

NCT07354659

Clinical Trials (5)

Showing 5 of 5 trials
NCT07505888Phase 3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years

Not Yet Recruiting
NCT07505836Phase 3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months

Not Yet Recruiting
NCT07505823Phase 3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months

Not Yet Recruiting
NCT07505810Phase 3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months

Not Yet Recruiting
NCT07354659Phase 2

Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5